Vipadenant (, ; developmental code name BIIB014 and others) is an adenosine A<sub>2A</sub> receptor antagonist which was under development for the treatment of Parkinson's disease and cancer but was never marketed. It is taken orally. The drug was first described in the scientific literature by 2006. It was under development by Vernalis, Biogen, and Juno Therapeutics. Vipadenant reached phase 2 clinical trials prior to the discontinuation of its development.